Detalhe da pesquisa
1.
Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.
Neurourol Urodyn
; 38(2): 779-792, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30644570
2.
Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
J Urol
; 196(3): 809-18, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27063854
3.
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Lancet Oncol
; 14(13): 1287-94, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24206640
4.
Novel Approach for Endoscopic Management of Duodenal Injury during Perirenal Infected Haematoma Drainage after Shock-Wave Lithotripsy.
Case Rep Urol
; 2018: 2020572, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30009077
5.
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Eur Urol
; 74(4): 501-509, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29866467
6.
Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.
Clin Genitourin Cancer
; 15(1): 72-76, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27498023
7.
Mutation analysis of the BRG1 gene in prostate cancer clinical samples.
Int J Oncol
; 22(5): 1003-7, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12684665
8.
Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.
Urology
; 104: 1-4, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28322904